Prove value
A risk-adjusted value built line by line from patients to present value, with a source and a confidence level behind every assumption. rNPV software ready for the board, the partner and the data room.
Every line of the forecast carries its value, confidence, impact and source, so the answer to "where did that number come from?" is already on the page. When a CFO, a partner or a data-room analyst asks, you point, not follow up.
Scenarios (50-50, Lead, Upside) and competitive strategies (Lead vs Second to Market) show the range a partner or investor will test, before they test it. The risk-adjusted NPV holds its shape because you have already stretched it.
The forecast report, the NPV overview and the one-page product profile export to Excel and PDF, so one approved case feeds every audience: the board pack, the partner's model and the data room.
One connected case
The value is built on the approved forecast, which is built on the approved target profile.
FAQ
Pixen builds the risk-adjusted NPV on your approved forecast. It applies probability of success by development phase, development and commercial costs, a discount rate you set and one of two terminal-value methods. Every input carries its source and confidence.
Patient-based forecasts built as a waterfall: eligible population, uptake, share, patients reached, regimen and doses, and net price, country by country. Valuation archetypes currently cover vaccines and preventive products; other modalities will follow.
Yes. The forecast report, NPV overview and one-page product profile export to Excel and PDF.
Once a case is approved, its calculations lock. Changes happen in a new version, and the activity log keeps who changed what, and when.
